Posted inStock
Novo Nordisk shares rebound despite disappointing CagriSema trial results
Investing.com — Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the release of data from the REDEFINE-1 phase…